LY2795050 | CAS#1346133-08-1| KOR antagonist

MedKoo Cat#: 565465 | Name: LY2795050

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LY2795050 is a novel kappa opioid receptor selective antagonist.

Chemical Structure

LY2795050

CAS#1346133-08-1 (free base)

Theoretical Analysis

MedKoo Cat#: 565465

Name: LY2795050

CAS#: 1346133-08-1 (free base)

Chemical Formula: C23H22ClN3O2

Exact Mass: 407.1401

Molecular Weight: 407.90

Elemental Analysis: C, 67.73; H, 5.44; Cl, 8.69; N, 10.30; O, 7.84

Price and Availability

Size	Price	Availability
200mg	USD 2,850.00	2 Weeks
500mg	USD 3,650.00	2 Weeks
1g	USD 5,450.00	2 Weeks
2g	USD 8,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1346133-08-1 (free base) 1346133-08-1 (HCl)

Synonym

LY2795050; LY 2795050; LY-2795050; (S)-LY2795050

IUPAC/Chemical Name

3-Chloro-4-[4-[[(2S)-2-pyridin-3-ylpyrrolidin-1-yl]methyl]phenoxy]benzamide

InChi Key

LOOCZNLSXJHWTG-NRFANRHFSA-N

InChi Code

InChI=1S/C23H22ClN3O2/c24-20-13-17(23(25)28)7-10-22(20)29-19-8-5-16(6-9-19)15-27-12-2-4-21(27)18-3-1-11-26-14-18/h1,3,5-11,13-14,21H,2,4,12,15H2,(H2,25,28)/t21-/m0/s1

SMILES Code

O=C(N)C1=CC=C(OC2=CC=C(CN3[C@H](C4=CC=CN=C4)CCC3)C=C2)C(Cl)=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

LY2795050 is a short-acting selective κ(kappa)-opioid receptor (KOR) antagonist.

In vitro activity:

The in vitro binding affinity of LY2795050 was measured in radioligand competition binding assays. LY2795050 displays full antagonist activity and high binding affinity and selectivity for KOR. Reference: J Nucl Med. 2013 Mar;54(3):455-63. https://pubmed.ncbi.nlm.nih.gov/23353688/

In vivo activity:

U50,488 produced dose-dependent grooming deficits in male and female mice, and LY2795050 prevented these effects. In contrast, LY2795050 decreased immobility in the FST in males at a dose of 0.1 mg/kg, but not in females, up to a dose of 0.32 mg/kg. Also, LY2795050 (0.32 mg/kg) prevented and also reversed the locomotor-depressant effects of U50,488 (10 mg/kg), in males and females. Reference: J Psychopharmacol. 2021 May;35(5):579-590. https://pubmed.ncbi.nlm.nih.gov/33769112/

	Solvent	mg/mL	mM
Solubility
	DMSO	50.0	122.58

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 407.90 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Zheng MQ, Nabulsi N, Kim SJ, Tomasi G, Lin SF, Mitch C, Quimby S, Barth V, Rash K, Masters J, Navarro A, Seest E, Morris ED, Carson RE, Huang Y. Synthesis and evaluation of 11C-LY2795050 as a κ-opioid receptor antagonist radiotracer for PET imaging. J Nucl Med. 2013 Mar;54(3):455-63. doi: 10.2967/jnumed.112.109512. Epub 2013 Jan 25. PMID: 23353688; PMCID: PMC3775344. 2. Baynard C, Prisinzano TE, Butelman ER. Rapid-Onset Anti-Stress Effects of a Kappa-Opioid Receptor Antagonist, LY2795050, Against Immobility in an Open Space Swim Paradigm in Male and Female Mice. Front Pharmacol. 2021 Nov 22;12:775317. doi: 10.3389/fphar.2021.775317. PMID: 34880762; PMCID: PMC8645979. 3. Butelman ER, Baynard C, McElroy BD, Prisinzano TE, Kreek MJ. Profile of a short-acting κ-antagonist, LY2795050, on self-grooming behaviors, forced swim test and locomotor activity: sex comparison in mice. J Psychopharmacol. 2021 May;35(5):579-590. doi: 10.1177/0269881121996883. Epub 2021 Mar 26. PMID: 33769112.

In vitro protocol:

In vivo protocol:

1. Baynard C, Prisinzano TE, Butelman ER. Rapid-Onset Anti-Stress Effects of a Kappa-Opioid Receptor Antagonist, LY2795050, Against Immobility in an Open Space Swim Paradigm in Male and Female Mice. Front Pharmacol. 2021 Nov 22;12:775317. doi: 10.3389/fphar.2021.775317. PMID: 34880762; PMCID: PMC8645979. 2. Butelman ER, Baynard C, McElroy BD, Prisinzano TE, Kreek MJ. Profile of a short-acting κ-antagonist, LY2795050, on self-grooming behaviors, forced swim test and locomotor activity: sex comparison in mice. J Psychopharmacol. 2021 May;35(5):579-590. doi: 10.1177/0269881121996883. Epub 2021 Mar 26. PMID: 33769112.

1: Butelman ER, McElroy BD, Prisinzano TE, Kreek MJ. Impact of Pharmacological Manipulation of the κ-Opioid Receptor System on Self-grooming and Anhedonic-like Behaviors in Male Mice. J Pharmacol Exp Ther. 2019 Jul;370(1):1-8. doi: 10.1124/jpet.119.256354. Epub 2019 Apr 11. PubMed PMID: 30975792; PubMed Central PMCID: PMC6538891. 2: Li S, Zheng MQ, Naganawa M, Kim S, Gao H, Kapinos M, Labaree D, Huang Y. Development and In Vivo Evaluation of a κ-Opioid Receptor Agonist as a PET Radiotracer with Superior Imaging Characteristics. J Nucl Med. 2019 Jul;60(7):1023-1030. doi: 10.2967/jnumed.118.220517. Epub 2019 Jan 10. PubMed PMID: 30630942; PubMed Central PMCID: PMC6604690. 3: Yang L, Brooks AF, Makaravage KJ, Zhang H, Sanford MS, Scott PJH, Shao X. Radiosynthesis of [(11)C]LY2795050 for Preclinical and Clinical PET Imaging Using Cu(II)-Mediated Cyanation. ACS Med Chem Lett. 2018 Nov 13;9(12):1274-1279. doi: 10.1021/acsmedchemlett.8b00460. eCollection 2018 Dec 13. PubMed PMID: 30613339; PubMed Central PMCID: PMC6295869. 4: Placzek MS, Schroeder FA, Che T, Wey HY, Neelamegam R, Wang C, Roth BL, Hooker JM. Discrepancies in Kappa Opioid Agonist Binding Revealed through PET Imaging. ACS Chem Neurosci. 2019 Jan 16;10(1):384-395. doi: 10.1021/acschemneuro.8b00293. Epub 2018 Oct 17. PubMed PMID: 30212182. 5: Vijay A, Cavallo D, Goldberg A, de Laat B, Nabulsi N, Huang Y, Krishnan-Sarin S, Morris ED. PET imaging reveals lower kappa opioid receptor availability in alcoholics but no effect of age. Neuropsychopharmacology. 2018 Dec;43(13):2539-2547. doi: 10.1038/s41386-018-0199-1. Epub 2018 Sep 6. PubMed PMID: 30188515; PubMed Central PMCID: PMC6224533. 6: Vijay A, Wang S, Worhunsky P, Zheng MQ, Nabulsi N, Ropchan J, Krishnan-Sarin S, Huang Y, Morris ED. PET imaging reveals sex differences in kappa opioid receptor availability in humans, in vivo. Am J Nucl Med Mol Imaging. 2016 Aug 20;6(4):205-14. eCollection 2016. PubMed PMID: 27648372; PubMed Central PMCID: PMC5004062. 7: Naganawa M, Dickinson GL, Zheng MQ, Henry S, Vandenhende F, Witcher J, Bell R, Nabulsi N, Lin SF, Ropchan J, Neumeister A, Ranganathan M, Tauscher J, Huang Y, Carson RE. Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050. J Pharmacol Exp Ther. 2016 Feb;356(2):260-6. doi: 10.1124/jpet.115.229278. Epub 2015 Dec 1. PubMed PMID: 26628406; PubMed Central PMCID: PMC4727157. 8: Naganawa M, Zheng MQ, Henry S, Nabulsi N, Lin SF, Ropchan J, Labaree D, Najafzadeh S, Kapinos M, Tauscher J, Neumeister A, Carson RE, Huang Y. Test-retest reproducibility of binding parameters in humans with 11C-LY2795050, an antagonist PET radiotracer for the κ opioid receptor. J Nucl Med. 2015 Feb;56(2):243-8. doi: 10.2967/jnumed.114.147975. Epub 2015 Jan 15. PubMed PMID: 25593119; PubMed Central PMCID: PMC4322754. 9: Pietrzak RH, Naganawa M, Huang Y, Corsi-Travali S, Zheng MQ, Stein MB, Henry S, Lim K, Ropchan J, Lin SF, Carson RE, Neumeister A. Association of in vivo κ-opioid receptor availability and the transdiagnostic dimensional expression of trauma-related psychopathology. JAMA Psychiatry. 2014 Nov;71(11):1262-70. doi: 10.1001/jamapsychiatry.2014.1221. Erratum in: JAMA Psychiatry. 2014 Nov;71(11):1301. PubMed PMID: 25229257. 10: Naganawa M, Zheng MQ, Nabulsi N, Tomasi G, Henry S, Lin SF, Ropchan J, Labaree D, Tauscher J, Neumeister A, Carson RE, Huang Y. Kinetic modeling of (11)C-LY2795050, a novel antagonist radiotracer for PET imaging of the kappa opioid receptor in humans. J Cereb Blood Flow Metab. 2014 Nov;34(11):1818-25. doi: 10.1038/jcbfm.2014.150. Epub 2014 Sep 3. PubMed PMID: 25182664; PubMed Central PMCID: PMC4269759. 11: Kim SJ, Zheng MQ, Nabulsi N, Labaree D, Ropchan J, Najafzadeh S, Carson RE, Huang Y, Morris ED. Determination of the in vivo selectivity of a new κ-opioid receptor antagonist PET tracer 11C-LY2795050 in the rhesus monkey. J Nucl Med. 2013 Sep;54(9):1668-74. doi: 10.2967/jnumed.112.118877. Epub 2013 Aug 5. PubMed PMID: 23918735; PubMed Central PMCID: PMC5824998. 12: Leung K. [Carbonyl-(11)C](S)-3-chloro-4-(4-((2-(pyridine-3-yl)pyrrolidin-1-yl)methyl)pheno xy)benzamide. 2013 Mar 21 [updated 2013 May 23]. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from http://www.ncbi.nlm.nih.gov/books/NBK138311/ PubMed PMID: 23700645. 13: Zheng MQ, Nabulsi N, Kim SJ, Tomasi G, Lin SF, Mitch C, Quimby S, Barth V, Rash K, Masters J, Navarro A, Seest E, Morris ED, Carson RE, Huang Y. Synthesis and evaluation of 11C-LY2795050 as a κ-opioid receptor antagonist radiotracer for PET imaging. J Nucl Med. 2013 Mar;54(3):455-63. doi: 10.2967/jnumed.112.109512. Epub 2013 Jan 25. PubMed PMID: 23353688; PubMed Central PMCID: PMC3775344. 14: Mitch CH, Quimby SJ, Diaz N, Pedregal C, de la Torre MG, Jimenez A, Shi Q, Canada EJ, Kahl SD, Statnick MA, McKinzie DL, Benesh DR, Rash KS, Barth VN. Discovery of aminobenzyloxyarylamides as κ opioid receptor selective antagonists: application to preclinical development of a κ opioid receptor antagonist receptor occupancy tracer. J Med Chem. 2011 Dec 8;54(23):8000-12. doi: 10.1021/jm200789r. Epub 2011 Oct 26. PubMed PMID: 21958337.